Holen Sie sich die Stockscreener-App
4.88
1.01%
-0.05
Handel nachbörslich:
4.87
-0.010
-0.20%
Schlusskurs vom Vortag:
$4.93
Offen:
$4.9
24-Stunden-Volumen:
126.03K
Relative Volume:
0.73
Marktkapitalisierung:
$286.46M
Einnahmen:
$30.91M
Nettoeinkommen (Verlust:
$-74.28M
KGV:
-4.0056
EPS:
-1.2183
Netto-Cashflow:
$-86.15M
1W Leistung:
+10.41%
1M Leistung:
-15.57%
6M Leistung:
+7.73%
1J Leistung:
+41.86%
1-Tages-Spanne:
$4.845
$5.10
1-Wochen-Bereich:
$4.52
$5.10
52-Wochen-Spanne:
$3.00
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.88 | 289.39M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Fortgesetzt | Jefferies | Buy |
| 2025-12-18 | Eingeleitet | BTIG Research | Buy |
| 2025-11-07 | Eingeleitet | Guggenheim | Buy |
| 2025-09-17 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
FHTX PE Ratio & Valuation, Is FHTX Overvalued - Intellectia AI
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
If You Invested $1,000 in Foghorn Therapeutics Inc. (FHTX) - Stock Titan
FHTX Technical Analysis & Stock Price Forecast - Intellectia AI
Strength Observed in Dianthus Therapeutics, Inc. (DNTH): Will Its 5.6% Increase Lead to Further Gains? - Bitget
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo! Finance Canada
FHTX Should I Buy - Intellectia AI
Aug Final Week: Can Foghorn Therapeutics Inc weather a recessionCPI Data & High Conviction Investment Ideas - baoquankhu1.vn
Setup Watch: Is Foghorn Therapeutics Inc part of any major index2026 Price Action Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Fundamentals Check: Is Foghorn Therapeutics Inc stock a good dividend stock2026 Earnings Impact & Daily Profit Focused Stock Screening - baoquankhu1.vn
FHTX Stock Price, Quote & Chart | FOGHORN THERAPEUTICS INC (NASDAQ:FHTX) - ChartMill
Ideas Watch: Is Foghorn Therapeutics Inc stock a hidden gem2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn
Citizens reiterates Foghorn Therapeutics stock rating on pipeline progress By Investing.com - Investing.com Canada
What is HC Wainwright's Forecast for FHTX FY2026 Earnings? - MarketBeat
Foghorn Therapeutics’ (FHTX) Outperform Rating Reiterated at Wedbush - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
FY2030 Earnings Estimate for FHTX Issued By HC Wainwright - Defense World
Brokers Offer Predictions for FHTX FY2030 Earnings - MarketBeat
Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Foghorn Therapeutics (FHTX) FY 2025 Losses Reinforce Bearish Unprofitability Narrative - Sahm
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data By Investing.com - Investing.com Australia
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data - Investing.com India
Foghorn Therapeutics reports $158.9M cash position, extends runway - Investing.com Australia
Foghorn Therapeutics (NASDAQ:FHTX) Earns "Outperform" Rating from Wedbush - MarketBeat
Stifel reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com Australia
Stifel reiterates Foghorn Therapeutics stock rating at buy - Investing.com
Foghorn Therapeutics: Pioneering Precision Oncology with Chromatin Regulatory System Targeting and Gene Traffic Control Platform - Minichart
Foghorn Advances FHD-909 Trial and Strengthens Financial Position - TipRanks
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - Bitget
Foghorn Therapeutics Inc. (FHTX) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 10-K: $30.9M revenue, $(1.18) EPS - TradingView
Foghorn Therapeutics (NASDAQ:FHTX) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Foghorn Therapeutics (FHTX) maps chromatin-targeting cancer pipeline with Lilly - Stock Titan
Foghorn Therapeutics (NASDAQ: FHTX) narrows 2025 loss and extends cash runway into 2028 - Stock Titan
Cancer drug developer Foghorn raises $50M, funds work on hard-to-treat tumors - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Given Buy Rating at HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Foghorn Therapeutics (NASDAQ:FHTX) - MarketBeat
HC Wainwright Reiterates Buy Rating for Foghorn Therapeutics (FH - GuruFocus
Aug Volume: Is Foghorn Therapeutics Inc part of any major index2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Will Foghorn Therapeutics Inc. stock benefit from AI adoptionForecast Cut & Smart Investment Allocation Insights - Naître et grandir
Foghorn Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
FHTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TD Cowen Health Care Conference - marketscreener.com
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):